The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2023 | Highlights at ASCO 2023
Nikolaos Trikalinos, MD, MS, Washington University, St. Louis, MO, shares his key takeaways from ASCO 2023, highlights the Phase III PROSPECT (NCT01515787) trial which focuses on optimizing treatment tolerance for patients. The trial specifically addresses the deescalation of radiation in patients with rectal cancer. This is significant news, especially for younger patients or those who face challenges in accessing or affording radiation therapy. The findings of the prospect trial offer promising opportunities to improve treatment options and outcomes for these specific patient populations. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
